Sort
35,931 grants matching “parkinsons”
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** PARKINSON'S DISEASE (PD) IS THE SECOND MOST COMMON NEURODEGENERATIVE DISEASE NEXT TO ALZHEIMER'S DISEASE, AFFECTING ABOUT 1-2% OF THE POPULATION OLDER THAN 60 YEARS OF AGE. NEARLY1 MILLION PEOPLE IN THE U.S. ARE LIVING WITH PD, AND THE NUMBER IS PREDICTED TO RISE TO 1.2 MILLION BY 2030. THE PD IS BECOMING MORE COMMON, AND BEING RECOGNIZED AS AN IMPORTANT PUBLIC HEALTH CONCERN, AS THE NEURODEGENERATIVE DISORDER CAUSES A GROWING MORTALITY RATE WORLDWIDE, PARTICULARLY IN THE ELDERLY. THE PD ALSO HAS IMPOSED A CONSIDERABLE SOCIAL-ECONOMIC BURDEN AND INCREASE IN MEDICAL EXPENSES. THE HEALTHCARE COSTS RELATED TO PD IS ESTIMATED TO BE NEARLY $ 52 BILLION PER YEAR IN THE UNITED STATES. TEA IS ONE OF THE MOST POPULAR BEVERAGES CONSUMED ACROSS THE WORLD. TEA CONTAINS A MIXTURE OF NATURAL FLAVONOIDS, CALLED TEA CATECHINS (TCS) WHICH OFFER A SPECTRUM OF HEALTH BENEFITS TO ANIMALS AND HUMANS, INCLUDING PROTECTIONS FROM CARDIOVASCULAR DISEASES, CANCERS, AS WELL AS NEURODEGENERATIVE DISEASES, INCLUDING PARKINSON'S DISEASE (PD). THE HUMAN STUDIES IN JAPAN, UNITED STATES AND FINLAND HAVE SUGGESTED PRESENCE OF A RELATIONSHIP BETWEEN TEA CONSUMPTION AND LOWER RATES OF COGNITIVE IMPAIRMENT AND THE RISK OF PD. THE LONG-TERM GOAL OF THIS RESEARCH IS TO INVESTIGATE THE THERAPEUTIC AND PREVENTIVE EFFECTS OF FOOD BIOACTIVE COMPOUNDS ON TREATMENT AND PREVENTION OF CHRONIC HUMAN DISEASES. THE IMMEDIATE GOAL OF THIS RESEARCH IS TO STUDY THE EFFECTS OF TEA COMPONENTS ON PROTECTION OF NEURON DAMAGE IN TRANSGENIC PD MOUSE MODEL AND TRANSGENIC PD NEMATODES MODEL AND TO EXAMINE ROLES OF COMPOSITION OF THE GUT MICROBES AND GUT-MICROBES-DEPENDENT METABOLISM IN MODULATION OF EFFICACIES OF TEA COMPONENTS IN PROTECTION OF BRAIN NEURONS.
$650,000University Of Georgia Research Foundation, Inc. · · FY2022 · National Institute of Food and Agriculture
An examination of psychomotor disturbance in current and remitted MDD: An RDoC Study
$649,974Stewart Aaron Shankman · Northwestern University At Chicago · R01 · FY2022 · MH
Development of soluble epoxide hydrolase inhibitors for the treatment of Alzheimer's disease
$649,899Kin Sing Stephen Lee · Michigan State University · R01 · FY2023 · AG
Development and Validation of a Self-Efficacy Item Bank
$649,834Lisa M. Shulman · University Of Maryland Baltimore · U01 · FY2010 · AR
Genotype-Phenotype Relationships in Fragile X Families
$649,652Randi J Hagerman · University Of California At Davis · R01 · FY2023 · HD
Anosmia as a predictor of preclinical Alzheimer's disease
$649,633Stavros Lomvardas · Columbia University Health Sciences · R56 · FY2019 · AG
Leucine rich repeat kinase 2 and dominantly inherited Parkinson disease
$649,605Mark Cookson · National Institute On Aging · ZIA · FY2012 · AG
Function and Pathogenic Mechanism of LRRK2 in Parkinson's Disease
$649,597Huaibin Cai · National Institute On Aging · ZIA · FY2019 · AG
Multimodal MRI markers of nigrostriatal pathology in Parkinson's disease
$649,506Xuemei Huang · Pennsylvania State Univ Hershey Med Ctr · U01 · FY2012 · NS
TRAINING GRANT ON THE BIOLOGY OF AGING
$649,488University Of Texas Hlth Sci Ctr San Ant · T32 · FY2004 · AG
Imaging Genomics of the Aging Brain
$649,474David C Glahn · Boston Children'S Hospital · R01 · FY2019 · AG
Corticostriatal mechanisms of action learning and habit formation
$649,355David M Lovinger · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2010 · AA
Multi-tissue high-throughput proteomic and genomic study in Parkinson's Disease
$649,168Bruno A. Benitez · Beth Israel Deaconess Medical Center · R01 · FY2022 · NS
Pathogenesis of Essential Tremor: Cerebellar Metabolism
$649,065Elan D Louis · Columbia University Health Sciences · R01 · FY2012 · NS
Advancing CAP4196 into in vivo Proof of Concept Translational Studies
$648,986Albert Remacle · Plex Pharmaceuticals, Inc. · R44 · FY2021 · EY
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium
$648,974Shiqian Shen · Massachusetts General Hospital · R01 · FY2024 · AG
SUMO family Ubiquitin-like Modifiers In Higher Eukaryotes
$648,905Mary C. Dasso · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · Z01 · FY2008 · HD
Imaging Biomarkers of Neurotoxicity in Welders
$648,694Brad A Racette · Washington University · R01 · FY2021 · ES
Human Dopamine Grafts in Alpha-Synuclein Models of Parkinson Disease
$648,551Viviane Tabar · Sloan-Kettering Inst Can Research · R01 · FY2025 · NS
Analysis and characterization of a cohort of familial Parkinson's disease exomes
$648,444John E. Landers · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · NS
The Neural Bases of Placebo Effects and their Relation to Regulatory Processes
$648,290Tor Dessart Wager · University Of Colorado · R01 · FY2015 · MH
Dopamine and Frontostriatal Function
$648,019Mark D'esposito · University Of California Berkeley · R01 · FY2017 · DA
A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
$648,003Paul S. Aisen · University Of California, San Diego · R01 · FY2011 · AG
CYClical Lower Extremity exercise for Parkinsons trial (CYCLE Trial)
$647,848Jay L Alberts · Cleveland Clinic Lerner Com-Cwru · R01 · FY2019 · NS
Circulating Blood-Based Diagnostic for Mild Cognitive Impaired Victims
$647,759Eugenia Wang · Advanced Genomic Technology, Llc · R44 · FY2015 · AG